Cancer cell membrane-coated bacterial ghosts for highly efficient paclitaxel delivery against metastatic lung cancer

Dandan Ling,Xueli Jia,Ke Wang,Qiucheng Yan,Bochuan Yuan,Lina Du,Miao Li,Yiguang Jin

DOI: https://doi.org/10.1016/j.apsb.2023.08.012

IF: 14.903

2023-08-20

Acta Pharmaceutica Sinica B

Abstract:Chemotherapy is one of the major approaches for the treatment of metastatic lung cancer, although it is limited by the low tumor delivery efficacy of anticancer drugs. Bacterial therapy is emerging for cancer treatment due to its high immune stimulation effect; however, excessively generated immunogenicity will cause serious inflammatory response syndrome. Here, we prepared cancer cell membrane-coated liposomal paclitaxel-loaded bacterial ghosts (LP@BG@CCM) by layer-by-layer encapsulation for the treatment of metastatic lung cancer. The preparation processes were simple, only involving film formation, electroporation, and pore extrusion. LP@BG@CCM owned much higher 4T1 cancer cell toxicity than LP@BG due to its faster fusion with cancer cells. In the 4T1 breast cancer metastatic lung cancer mouse models, the remarkably higher lung targeting of intravenously injected LP@BG@CCM was observed with the almost normalized lung appearance, the reduced lung weight, the clear lung tissue structure, and the enhanced cancer cell apoptosis compared to its precursors. Moreover, several major immune factors were improved after administration of LP@BG@CCM, including the CD4 + /CD8a + T cells in the spleen and the TNF- α , IFN- γ , and IL-4 in the lung. LP@BG@CCM exhibits the optimal synergistic chemo-immunotherapy, which is a promising medication for the treatment of metastatic lung cancer.

pharmacology & pharmacy

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to improve the delivery efficiency and efficacy of chemotherapy drugs for metastatic lung cancer while reducing their toxicity and side effects. Specifically:

1. **Improve the delivery efficiency of anticancer drugs**: When traditional chemotherapy drugs are used to treat metastatic lung cancer, the low delivery efficiency leads to poor efficacy. This paper proposes a new type of drug carrier - liposome - paclitaxel - loaded bacterial ghosts coated with cancer cell membranes (LP@BG@CCM) in order to increase the enrichment of drugs at the tumor site.

2. **Enhance the immunostimulatory effect**: Bacterial therapy has attracted much attention in cancer treatment because of its strong immunostimulatory effect, but excessive immune response may lead to severe inflammatory response syndrome. By using bacterial ghosts coated with cancer cell membranes, this excessive immune response can be weakened, thus achieving safer and more effective combined chemotherapy - immunotherapy.

3. **Reduce drug toxicity and side effects**: The toxicity and side effects of traditional chemotherapy drugs have always been the main obstacles in clinical applications. By optimizing the design of drug carriers, the damage to normal tissues can be reduced while improving the efficacy.

### Specific solutions in the paper

The authors designed and prepared liposome - paclitaxel - loaded bacterial ghosts coated with cancer cell membranes (LP@BG@CCM) and achieved the above goals through the following steps:

1. **Preparation of bacterial ghosts (BGs)**: By controlling the expression of phage 4X174 gene E, Escherichia coli is lysed to form bacterial ghosts with an empty - shell - like structure.

2. **Preparation of liposome - paclitaxel (LP)**: Paclitaxel is encapsulated in liposomes to form a stable drug carrier.

3. **Layer - by - layer encapsulation**: First, LP is encapsulated into BGs to form LP@BG, and then LP@BG is coated with cancer cell membranes (CCMs) to finally form LP@BG@CCM.

### Experimental results

- **In vivo experiments**: In the 4T1 breast cancer lung - metastasis mouse model, after intravenous injection of LP@BG@CCM, significant lung targeting was observed, the lung tissue structure was clear, cancer cell apoptosis was enhanced, and the appearance of the lungs almost returned to normal.

- **Improvement of immune factors**: After drug administration, the ratio of CD4⁺/CD8⁺ T cells in the spleen and the levels of TNF - α, IFN - γ and IL - 4 in the lungs were all increased.

- **Combined chemotherapy - immunotherapy**: LP@BG@CCM showed the best combined chemotherapy - immunotherapy effect, providing a promising new method for the treatment of metastatic lung cancer.

Through these improvements, this study aims to develop an efficient and safe drug delivery system to meet the challenges in the treatment of metastatic lung cancer.